Suppr超能文献

表皮生长因子受体在高级别骨肉瘤中的表达与良好的临床结果相关。

Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.

作者信息

Kersting Christian, Gebert Carsten, Agelopoulos Konstantin, Schmidt Hartmut, van Diest Paul J, Juergens Heribert, Winkelmann Winfried, Kevric Matthias, Gosheger Georg, Brandt Burkhard, Bielack Stefan, Buerger Horst

机构信息

Institute of Pathology, University of Münster, Münster, Germany.

出版信息

Clin Cancer Res. 2007 May 15;13(10):2998-3005. doi: 10.1158/1078-0432.CCR-06-2432.

Abstract

PURPOSE

The expression of the epidermal growth factor receptor (EGFR) in osteosarcomas has repeatedly been described. With the introduction of anti-EGFR-targeted therapies in clinical practice, these findings regain increased attention. Experience with anti-EGFR-targeted therapies in other cancers has made clear that besides the expression status of EGFR, a detailed knowledge about gene mutations is of major predictive power. We therefore aimed to explore the EGFR expression and gene mutation status in high-grade osteosarcomas.

EXPERIMENTAL DESIGN

We investigated tumor samples of osteosarcoma patients of all age groups by means of immunohistochemistry (n=111) and egfr fluorescence in situ hybridization (n=39). Sixty-three patients were treated according to the Cooperative Osteosarcoma Study Group protocols and complete clinical follow-up was available in these cases.

RESULTS

Ninety-one of 111 (81%) of osteosarcomas revealed an expression of EGFR. EGFR expression showed a dose-response relation with improved event-free and overall survival. This was independent of the degree of tumor regression due to neoadjuvant chemotherapy. Nine of 39 (23%) osteosarcomas showed egfr amplifications by means of fluorescence in situ hybridization. All these cases expressed EGFR. When comparing EGFR expression between primary biopsy and resection specimen (n=19), viable residual tumor cells in resection specimens revealed a lower EGFR expression and a tendency toward membranous staining compared with the initial biopsy.

CONCLUSIONS

In conclusion, expression and amplification of EGFR are frequently observed in high-grade osteosarcomas and are associated with improved prognosis in a dose-responsive way. This implies that low EGFR expression possibly predicts lack of response to conventional treatment in high-grade osteosarcomas and may warrant a more intensive therapeutic approach, although not based on EGFR targeting.

摘要

目的

表皮生长因子受体(EGFR)在骨肉瘤中的表达已被多次报道。随着抗EGFR靶向治疗在临床实践中的引入,这些发现再次受到更多关注。在其他癌症中使用抗EGFR靶向治疗的经验表明,除了EGFR的表达状态外,对基因突变的详细了解具有重要的预测价值。因此,我们旨在探讨高级别骨肉瘤中EGFR的表达和基因突变状态。

实验设计

我们通过免疫组织化学(n = 111)和EGFR荧光原位杂交(n = 39)对所有年龄组骨肉瘤患者的肿瘤样本进行了研究。63例患者按照骨肉瘤协作研究组方案进行治疗,这些病例有完整的临床随访资料。

结果

111例骨肉瘤中有91例(81%)显示EGFR表达。EGFR表达与无事件生存期和总生存期的改善呈剂量反应关系。这与新辅助化疗导致的肿瘤退缩程度无关。39例骨肉瘤中有9例(23%)通过荧光原位杂交显示EGFR扩增。所有这些病例均表达EGFR。在比较原发活检和切除标本(n = 19)之间的EGFR表达时,切除标本中存活的残留肿瘤细胞与初始活检相比,EGFR表达较低,且有膜性染色倾向。

结论

总之,在高级别骨肉瘤中经常观察到EGFR的表达和扩增,并且以剂量反应方式与预后改善相关。这意味着低EGFR表达可能预示高级别骨肉瘤对传统治疗无反应,可能需要更强化的治疗方法,尽管不是基于EGFR靶向治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验